Orthogon Therapeutics, a privately held research and development (R&D) company, uses principles of biophysics and structure-based drug design to develop anti-infective small molecules that ...

This has heightened the company’s core competencies in small-molecule drug design and synthesis and early development, resulting in a rich pipeline. Shionogi’s infectious disease portfolio of ...

A new company set up to use machine learning to find new anti-infective drugs – ArrePath – has launched onto the scene with $20 million in seed financing from a group of investors including ...

There is an urgent need for the discovery of new drugs against infectious diseases and cancer. Globally, infectious diseases are prevalent, with pathogens constantly evolving, leading to a rise in ...